Commentary: Evaluating disease modifying treatments in multiple sclerosis

British Medical Journal

Volumn 326, Issue 7388, 2003, Pages 525-

  Miller, David H ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER;

DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RELAPSE; SOCIOECONOMICS;

EID: 0037426005     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Rice GPA, Incorvaia B, Munari L, Ebers G, Pohnan C, D'Amico R, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Library. Issue 4. Oxford: Update Software, 2001.
2. National Institute for Clinical Excellence. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. Technology appraisal guidance. www.nice.org.uk [No 32, Jan 2002.]
3. Association of British Neurologists. Guidelines for the use of beta interferons and glatiramer acetate in multiple sclerosis, Jan 2001. www.theabn.org
4. Noseworthy J, Kappos L, Daumer M. Competing interests in multiple sclerosis research. Lancet 2003;361:350-1.